Pósfai Éva, Irsai Gábor, Illés Árpád, Méhes Gábor, Marton Imelda, Molnár Csaba, Csípő István, Baráth Sándor, Gergely Lajos
2nd Department of Medicine and Cardiology Center, Medical Faculty, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary.
Pathol Oncol Res. 2014 Jul;20(3):649-54. doi: 10.1007/s12253-014-9744-3. Epub 2014 Feb 1.
The use of rituximab brought attention to the hosts' immune system and to the microenvironment in non-Hodgkin's lymphoma cases. Our aim was to identify prognostic factors that can be measured easily to indicate the current state of the patient's immune status and possible reaction against malignant cells. In the retrospective analysis (2000-2008), 66 patients diagnosed with B-cell non-Hodgkin's lymphomas were enrolled (40 women, 26 men; mean age: 51 years). White blood cells, lymphocytes, CD3 +; CD4 +; CD8 + T-cells, immunoglobulin types A; G; M, anti-cardiolipin antibody isotypes A; G; M; and levels of beta-2-microglobulin were measured before the initiation of the first cycle of chemotherapy, during and after 4-weeks treatment. As for CD 3+ T-lymphocytes, the absolute CD 3+ T -lymphocyte numbers were higher before (0.78 × 10(9)/L) versus during (0.27 × 10(9)/L) treatment, and increased percentages were detected in pre- (66.57 %) and post-treatment (75.32 %). Absolute numbers of CD 8+ T-lymphocyte levels showed reduction before (0.26 × 10(9)/L) versus during (0.10 × 10(9)/L) therapy, but were elevated after (0.28 × 10(9)/L) treatment, while increased percentage before (21.99 %) versus after (29.85 %), and during (24.56 %) versus after (29.85 %) therapy were seen. Average white blood cell numbers were increased before (9.71 × 10(9)/L) versus during (12.07 × 10(9)/L) treatment, while decreased numbers could be observed, after (5.47 × 10(9)/L) treatment. IgA levels were decreased before (2.51 g/L) versus after (1.63 g/L) therapy. IgG levels were higher before (12.25 g/L) vs. after (8.64 g/L) treatment. IgM levels were decreased before (1.76 g/L) and after (0.83 g/L) as well as before (1.76 g/L) versus during (0.73 g/L) treatment. Anti-cardiolipin antibody type A level were decreased before (2.76 U/ml) versus after (2.49 U/ml) treatment. Decreased level of beta-2-microglobulin could be observed before (2.91 mg/L) versus post (2.28 mg/L) chemotherapy. Findings may provide better insight into the effects of immuno-chemotherapy on the hosts' immune system.
利妥昔单抗的使用使人们关注到非霍奇金淋巴瘤病例中宿主的免疫系统和微环境。我们的目的是确定易于测量的预后因素，以指示患者当前的免疫状态以及对恶性细胞可能的反应。在回顾性分析（2000 - 2008年）中，纳入了66例诊断为B细胞非霍奇金淋巴瘤的患者（40名女性，26名男性；平均年龄：51岁）。在化疗第一周期开始前、治疗4周期间及治疗后，测量白细胞、淋巴细胞、CD3 +、CD4 +、CD8 + T细胞、免疫球蛋白A、G、M型、抗心磷脂抗体A、G、M型以及β2 - 微球蛋白水平。至于CD3 + T淋巴细胞，绝对CD3 + T淋巴细胞数量在治疗前（0.78×10⁹/L）高于治疗期间（0.27×10⁹/L），且治疗前（66.57%）和治疗后（75.32%）检测到百分比增加。CD8 + T淋巴细胞水平的绝对数量在治疗前（0.26×10⁹/L）高于治疗期间（0.10×10⁹/L），但治疗后（0.28×10⁹/L）升高，同时治疗前（21.99%）与治疗后（29.85%）以及治疗期间（24.56%）与治疗后（29.85%）相比，百分比增加。平均白细胞数量在治疗前（9.71×10⁹/L）高于治疗期间（12.07×10⁹/L），而治疗后（5.47×10⁹/L）可观察到数量减少。IgA水平在治疗前（2.51 g/L）低于治疗后（1.63 g/L）。IgG水平在治疗前（12.25 g/L）高于治疗后（8.64 g/L）。IgM水平在治疗前（1.76 g/L）和治疗后（0.83 g/L）以及治疗前（1.76 g/L）低于治疗期间（0.73 g/L）。抗心磷脂抗体A型水平在治疗前（2.76 U/ml）低于治疗后（2.49 U/ml）。化疗前（2.91 mg/L）与化疗后（2.28 mg/L）相比，可观察到β2 - 微球蛋白水平降低。这些发现可能有助于更好地了解免疫化疗对宿主免疫系统的影响。
